Evonik, Ties

Evonik Ties Divestment Terms to Site Guarantees as BlackRock Cuts Stake and BASF Circles

Published on 11/17/2026 at 16:41 | Editorial boerse-global.de
Evonik's board letter sets long-term commitments for buyers of Oxeno and Syneqt units, not a BASF takeover blueprint; BlackRock cuts its stake to 5.08%.
Evonik, Ties, Divestment, Terms, Site, Guarantees, BlackRock, Cuts, Stake, BASF Illustration mit AI erstellt.

Evonik is demanding firm long-term commitments from any buyer of the businesses it has put on the block, according to an internal board letter that surfaced this week — a document that has been read in some quarters as a signal on the BASF approach, but which in fact concerns the sale of individual units rather than the group as a whole.

The letter, reported by dpa-AFX, sets out what future owners of the divested operations must provide: viable long-term prospects for the sites, plus continued adherence to key agreements covering collective bargaining, pensions and vocational training. Media reports add that Evonik also wants buyers to invest in the competitiveness of the businesses concerned. On the block are the Oxeno division and the Syneqt chemical park activities, tying commercial expectations to safeguards for the workforce.

A standalone path, not a takeover blueprint

Bloomberg initially interpreted the internal letter as conditions for a possible takeover by BASF. According to dpa-AFX, however, it applies to purchasers of individual business units, so no rapprochement on a full-scale merger can be inferred from its contents. Proceeds from any sales are to stay inside the company and strengthen its long-term capacity — part of Evonik's independent course rather than a set of terms for being absorbed.

BASF, for its part, has floated a possible offer of 24 euros per Evonik share, which would value the group at more than 11 billion euros. That figure is a potential bid, not a binding takeover offer, and no agreement has been reached. Evonik continues to insist on remaining independent, while BASF chief executive Markus Kamieth has made clear he will not overpay. Both the fundamental willingness to do a deal and its possible terms therefore remain open questions.

Should investors sell immediately? Or is it worth buying Evonik?

Shareholder register shifts

On the ownership side, BlackRock has reported a reduction in its voting rights in Evonik. The mandatory disclosure published yesterday showed the stake falling to 5.08% from 5.25%, with the threshold crossing dated 10 November. Shares accounted for 3.94% of the voting rights and instruments for a further 1.14%, a breakdown that separates the two components of the total reported position.

The takeover question has also been kept alive by Reuters, which reported on 9 November that Evonik maintained its rejection even after a meeting between the two companies' top management. No further meetings were initially planned, according to that report, with the gathering having taken place the previous weekend.

Operations deliver while the debate runs

Beneath the corporate maneuvering, the operating record has been firming. Evonik reported adjusted EBITDA of 629 million euros for the third quarter of 2026 on 3 November, and guided for full-year 2026 adjusted EBITDA in the upper half of a range of 2.0 to 2.2 billion euros.

Two production milestones landed within days of each other. At its new Lipid Innovation Center in Lafayette, Indiana, the company produced its first batch of pharmaceutical-grade lipids to GMP quality on 10 November, with full capacity due to be available by mid-2027. A day earlier, Evonik Oxeno said AI-based process models had been deployed in live plant operations at Marl and Antwerp for the first time, with the initial applications delivering higher energy efficiency and lower CO2 emissions; the models are intended to cut both energy consumption and plant emissions going forward.

Evonik at a turning point? This analysis reveals what investors need to know now.

What the share price does — and doesn't — say

The stock is up 3.4% today. That gain on its own is no evidence of progress toward a takeover. The substantive company news concerns the terms on which Evonik is prepared to part with individual activities.

What matters for the valuation from here is whether Evonik can find buyers able to combine commercial prospects with the required commitments — and how the intended proceeds are used to strengthen the remaining businesses. The board letter sets guardrails for exactly that. It is neither a completed sale nor a takeover agreement.

Ad

Evonik Stock: New Analysis - 17 November

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...

Disclaimer...
en | DE000EVNK013 | EVONIK | boerse | 70527673 |